The Company at its Board Meeting held today i.e. August 11, 2026 have approved Unaudited Financial Results of the Company (standalone and consolidated) for quarter ended June 30, 2026 and ....

August 11, 2026 BSE Limited, Corporate Relationship Department, P.J. Towers, Dalal Street, Mumbai 400 001 Scrip No. 543363 Sub: Outcome of the Board Meeting pursuant to Regulation 30 (Listing Obligations and Disclosure Requirements) Regulations, 2015 held on Tuesday, August 11, 2026. Dear Sir/Madam, With reference to the captioned subject and in compliance with Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of the Company at its Meeting held today i.e., Tuesday, August 11, 2026, inter-alia have considered and approved; 1. Unaudited Financial results for the quarter ended on June 30, 2026, in this regard, please find enclosed herewith: (a) Unaudited Financial Results (standalone and consolidated) of the Company for the quarter ended on June 30, 2026. (b) Limited Review Report in respect of the Unaudited Financial Results (standalone and consolidated) of the Company for the quarter ended on June 30, 2026. 2. Recommendation of payment of Final Dividend on Equity Shares at the rate of 10% (Ten per cent) [i.e, Rs. 1.00 (Rupees One Only) per Equity Share of Face Value of 10/- (Rupees Ten Only)] for the Financial Year ended March 31, 2026, subject to approval of shareholders at the ensuing Annual General Meeting. The dividend, if approved, shall be paid within the prescribed timeline. 3. Notice of 27th Annual General Meeting, Directors’ Report along with Management Discussion and Analysis Report for the financial year ended March 31, 2026. These are also being made available on the website of the Company at www.prevestdenpro.com The Meeting was commenced at 03.15 p.m. and concluded at 03:50 p.m. We request you to take the same on your record. Thanking You, Yours faithfully, For Prevest Denpro Limited Pratul Gupta Company Secretary & Compliance Officer Encl: As above MITTAL & ASSOCIATES B-603, Raylon Arcade, RK Mandir Road, CHARTERED ACCOUNTANTS Kondivita, JB nagar Andheri (East), Mumbai – 400059 Tel : 8689958800 Email : audit@mittal-associates.com INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED UNAUDITED FINANCIAL RESULTS THE BOARD OF DIRECTORS OF PREVEST DENPRO LIMITED, 1. We have reviewed the accompanying statement of Consolidated unaudited financial results ('the Statement') of PREVEST DENPRO LIMITED ('the Holding Company') and its Subsidiaries (together referred to as “the Group”) for the quarter ended 30th June, 2026 being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. 2. The Statement, which is the responsibility of the Holding company’s management and approved by the Holding Company’s Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25 “Interim Financial Reporting” prescribed under section 133 of the companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles and generally accepted in India, read with the circular Our responsibility is to issue a report on these financial statements based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Companies Act 2013, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. This statement Includes the results of the following entity – (i) Prevest Denpro Limited – Holding Company (ii) Denvisio Biomed Limited – Wholly owned subsidiary (iii) Axiodent Inc. – Wholly owned foreign subsidiary (iv) Prevest Denpro Gulf General Trading LLC - Wholly owned foreign subsidiary 5. We did not review the financial results of the wholly owned foreign subsidiaries Axiodent Inc. and Prevest Denpro Gulf General Trading LLC included in the consolidated financial results, whose financial results include total revenue (before consolidation adjustments) of Rs. 5.71 Lakhs and total net loss after tax (before consolidation adjustments) of Rs. 16.81 Lakhs for the quarter ended on that date. These financial results have been reviewed by Parent management and furnished to us and our conclusion on the statement, in so far relates to the amount and disclosure included in respect of subsidiary, is based solely on these managements certified financial results. According to the information and explanations given to us by the Management, these interim financial information / financial results are not material to the Group. Our conclusion on the Statement is not modified in respect of the above matters. 6. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including the manner in which it is to be disclosed, or that it contains any material misstatement. For Mittal & Associates Chartered Accountants FRN: 106456W Sourabh Bagaria Partner M. NO.: 183850 UDIN: 26183850OFCCVS7293 Place: Mumbai Date: 11th August, 2026 PREVESTDenPro® THE FUTURE OF DENTISTRY Statement of Consolidated Unaudited Financials Results for the Quarter ended on 30th June, 2026 * in Lakh, except per share data Quarter ended Year ended sr. No,| Particulars 30/06/2026] 31/03/2026 | 30/06/2025 | 31/03/2026 Unaudited | _Audited | Unaudited | _Audited 1 |income Revenue from operations 1,906.83 | 1,89406| 157663| 7,180.85 Other Income 131.53 140.61 116,61 49151 Total Income 2,038.36 | 2034.67| 1693.24| 7,672.36 2 [Expenses (a) Cost of Material Consumed 480.49 376.13 40644 | 178177 (b) Changes in inventories of finished goods, work-in-progress and stock-in- trade (51.39) 18.61 (50.58) -120.66 (c) Finance Cost - - - - (d) Employee benefit expenses 377.29 34331 30553 | 1,324.04 (e) Depreciation and amortization expenses 52.25 50.64 49.12 20088 (f) Other Expenses 423.83 464.98 38393| 172510 Total Expenses 1,282.47| 1,253.67| 1,094.43| 4,911.12 3 [Profit Before Tax (1-2) 755.89 781.00 598.82| 2,761.23 4 [TaxExpenses Current Tax 187.40 19291 152.39 690.36 Earlier Period Tax - . (121) - (3.76) Deffered Tax 4.63 7.6 5.89 25.59 Total Tax Expenses 192.03 198.86 158.28 712.19 5 [Net Profit for the Peiod/Year (3-4) 563.86 582.13 44054 | 2,043.05 6 |Earnings per Share (EPS) of 10 each, (not annualised for the quarter) (a) Basic 470 485 3.67 17.07 (b) Diluted 4.70 485 3.67 17.07 7_|Paid up Equity Share Capital-Face Value Rs 10/- each 120030 1,20030| 1,20030| 1,200.30 8 _|Reserve (excluding Revaluation Reserves) 11,279.52 Notes to Consolidated audited financial results: 1 The above unaudited consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors oft he Company at their meeting held on August 11, 2026, These unaudited standalone financial results arc prepared in accordance with the AS prescribed under Section 133 oft he Companies Act, 2013, The above unaudited standal [Showing first 8,000 characters — download PDF for full document]